Redeye: Embracer Group - Pipeline in Focus

Redeye reiterates its positive view of Embracer Group. The Q4 report was solid, and the update to the pipeline has not led to any significant changes to our forecasts. A substantial amount of available capital for M&A indicates that something big could be in the making. Embracers' quality and M&A track-record should justify a premium valuation; the company is still valued in line with peers based on Oper. EBIT multiples. We believe that the growth journey of Embracer Group will continue for many years more.

Read more and download the research update: https://bit.ly/Embracer-pipeline

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/